계명대학교 의학도서관 Repository

Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database

Metadata Downloads
Author(s)
Gil-Chun ParkShin HwangMyoung-Soo KimDong-Hwan JungGi-Won SongKwang-Woong LeeJong Man KimJae Geun LeeJe Ho RyuDong Lak ChoiHee-Jung WangBong-Wan KimDong-Sik KimYang Won NahYoung Kyoung YouKoo Jeong KangHee Chul YuYo-Han ParkKyung Jin LeeYun Kyu Kim
Keimyung Author(s)
Kang, Koo Jeong
Department
Dept. of Surgery (외과학)
Journal Title
Journal of Korean medical science
Issued Date
2020
Volume
35
Issue
6
Keyword
Hepatitis B VirusRecurrenceLiver TransplantationHepatitis B ImmunoglobulinAntiviral Agent
Abstract
Background:
Prophylaxis for hepatitis B virus (HBV) recurrence is essential after liver transplantation (LT) in HBV-associated recipients. We conducted real-world analysis of HBV prophylaxis after LT in the Korean population.

Methods:
Korean Organ Transplantation Registry (KOTRY) database and additionally collected data (n = 326) were analyzed with special reference to types of HBV prophylaxis.

Results:
The study cohort comprised 267 cases of living-donor LT and 59 cases of deceased-donor LT. Hepatocellular carcinoma (HCC) was diagnosed in 232 (71.2%) of these subjects. Antiviral agents were used in 255 patients (78.2%) prior to LT. HBV DNA was undetectable in 69 cases (21.2%) and detectable over wide concentrations in the other 257 patients (78.8%) prior to LT. Polymerase chain reaction analysis of the store blood samples detected HBV DNA in all patients, with 159 patients (48.9%) showing concentrations > 100 IU/mL. Post-transplant HBV regimens during the first year included combination therapy in 196 (60.1%), hepatitis B immunoglobulin (HBIG) monotherapy in 121 (37.1%), and antiviral monotherapy in 9 (2.8%). In the second post-transplant year, these regimens had changed to combination therapy in 187 (57.4%), HBIG monotherapy in 112 (34.4%), and antiviral monotherapy in 27 (8.3%). Trough antibody to hepatitis B surface antigen titers > 500 IU/mL and >1,000 IU/mL were observed in 61.7% and 25.2%, respectively. The mean simulative half-life of HBIG was 21.6 ± 4.3 days with a median 17.7 days. Up to 2-year follow-up period, HCC recurrence and HBV recurrence developed in 18 (5.5%) and 6 (1.8%), respectively. HCC recurrence developed in 3 of 6 patients with HBV recurrence.

Conclusion:
Combination therapy is the mainstay of HBV prophylaxis protocols in a majority of Korean LT centers, but HBIG was often administered excessively. Individualized optimization of HBIG treatments using SHL is necessary to adjust the HBIG infusion interval.
Keimyung Author(s)(Kor)
강구정
Publisher
School of Medicine (의과대학)
Citation
Gil-Chun Park et al. (2020). Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database. Journal of Korean medical science, 35(6), e36. doi: 10.3346/jkms.2020.35.e36
Type
Article
ISSN
1598-6357
Source
https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e36
DOI
10.3346/jkms.2020.35.e36
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/43177
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Surgery (외과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.